01/31/2013
Federal Register Notice: FDA’s proposed collection of information, “Inspection by Accredited Persons Program Under the...01/31/2013
Federal Register Notice: FDA has determined that Differin (adapalene) solution, 0.1% was not withdrawn from sale for reasons of sa...01/31/2013
Federal Register Notice: FDA will hold a public hearing 2/25 to obtain input on the agency’s regulation of drugs for treatin...01/31/2013
Federal Register Notice: FDA is correcting a date in a 1/7 Federal Register notice announcing a public workshop entitled “Ac...01/31/2013
Federal Register Notice: FDA has determined the regulatory review period for Pfizer’s Xalkori is 2,054 days for extending a ...